JP2007508392A - アリールアルキルおよびシクロアルキルアルキル−ピペラジン誘導体およびその使用方法 - Google Patents
アリールアルキルおよびシクロアルキルアルキル−ピペラジン誘導体およびその使用方法 Download PDFInfo
- Publication number
- JP2007508392A JP2007508392A JP2006535598A JP2006535598A JP2007508392A JP 2007508392 A JP2007508392 A JP 2007508392A JP 2006535598 A JP2006535598 A JP 2006535598A JP 2006535598 A JP2006535598 A JP 2006535598A JP 2007508392 A JP2007508392 A JP 2007508392A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- esi
- prepared
- piperazin
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WJSPKNSMGLBHBW-PKPIPKONSA-N C1[C@@H]2C=CCCC12 Chemical compound C1[C@@H]2C=CCCC12 WJSPKNSMGLBHBW-PKPIPKONSA-N 0.000 description 1
- XFBVHRKLWFEXDI-UHFFFAOYSA-N CC#Cc1cccc(C(CN2CCNCC2)C2(CCCCC2)O)c1 Chemical compound CC#Cc1cccc(C(CN2CCNCC2)C2(CCCCC2)O)c1 XFBVHRKLWFEXDI-UHFFFAOYSA-N 0.000 description 1
- ZVWXBRCSRSQGAP-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1(C(CN1CCNCC1)c1cc(Cl)ccc1)O Chemical compound CC(C)(C)C(CC1)CCC1(C(CN1CCNCC1)c1cc(Cl)ccc1)O ZVWXBRCSRSQGAP-UHFFFAOYSA-N 0.000 description 1
- XBZUYJXNRPLKHT-UHFFFAOYSA-N CC(C)(CC(C)(C)C1)CC1(C(CN1CCNCC1)c1cc(Cl)ccc1)O Chemical compound CC(C)(CC(C)(C)C1)CC1(C(CN1CCNCC1)c1cc(Cl)ccc1)O XBZUYJXNRPLKHT-UHFFFAOYSA-N 0.000 description 1
- DMPPVLSNDSVJMF-UHFFFAOYSA-N CC(CC1)CCC1(C(CN1CCN(C)CC1)c1cccc2ccccc12)O Chemical compound CC(CC1)CCC1(C(CN1CCN(C)CC1)c1cccc2ccccc12)O DMPPVLSNDSVJMF-UHFFFAOYSA-N 0.000 description 1
- UJUMNMYEMMYYEG-UHFFFAOYSA-N CC(CN1CCN(CC(C2(CCCCC2)O)c2cc(Cl)ccc2)CC1)c1ccccc1 Chemical compound CC(CN1CCN(CC(C2(CCCCC2)O)c2cc(Cl)ccc2)CC1)c1ccccc1 UJUMNMYEMMYYEG-UHFFFAOYSA-N 0.000 description 1
- MVCNSYULJDOMKA-DYHFLHIPSA-N CCC[C@@H](C)C(C)C[C@@H](CN1[C@H](C)NCC1)[C@H]1CC[C@@H](CCC)CC1 Chemical compound CCC[C@@H](C)C(C)C[C@@H](CN1[C@H](C)NCC1)[C@H]1CC[C@@H](CCC)CC1 MVCNSYULJDOMKA-DYHFLHIPSA-N 0.000 description 1
- ONSOEPDGSFRLQN-JAMMHHFISA-N CCC[C@H](C)CC(C)Cl Chemical compound CCC[C@H](C)CC(C)Cl ONSOEPDGSFRLQN-JAMMHHFISA-N 0.000 description 1
- SXZKHCDZDKNTSX-UHFFFAOYSA-N CCOc1ccc(C(CN2CCN(C)CC2)C2(CCCCC2)O)cc1OC(F)(F)F Chemical compound CCOc1ccc(C(CN2CCN(C)CC2)C2(CCCCC2)O)cc1OC(F)(F)F SXZKHCDZDKNTSX-UHFFFAOYSA-N 0.000 description 1
- FJEFSULYEQYQGY-UHFFFAOYSA-N CN(C)C1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2cc3ccccc3cc2)CC1 Chemical compound CN(C)C1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2cc3ccccc3cc2)CC1 FJEFSULYEQYQGY-UHFFFAOYSA-N 0.000 description 1
- TXCJJEGCTKWDGZ-UHFFFAOYSA-N CN(C)C1CCN(CC(C2(CCCCC2)O)c2cc(Cl)ccc2)CC1 Chemical compound CN(C)C1CCN(CC(C2(CCCCC2)O)c2cc(Cl)ccc2)CC1 TXCJJEGCTKWDGZ-UHFFFAOYSA-N 0.000 description 1
- GQXANPULLNSQAM-UHFFFAOYSA-N CN(C)C1CCN(CC(C2CCCC2)c2cc(Cl)ccc2)CC1 Chemical compound CN(C)C1CCN(CC(C2CCCC2)c2cc(Cl)ccc2)CC1 GQXANPULLNSQAM-UHFFFAOYSA-N 0.000 description 1
- WHMRLHZYHWUSOQ-PPUHSXQSSA-N CN(C)[C@H]1CN(CC(C2(CCCCC2)O)c2cccc3ccccc23)CC1 Chemical compound CN(C)[C@H]1CN(CC(C2(CCCCC2)O)c2cccc3ccccc23)CC1 WHMRLHZYHWUSOQ-PPUHSXQSSA-N 0.000 description 1
- AQKWOXKUZVAZIH-UHFFFAOYSA-N CN(CC1)CCC1(C(CN1CCOCC1)c(cc1)cc(Cl)c1Cl)O Chemical compound CN(CC1)CCC1(C(CN1CCOCC1)c(cc1)cc(Cl)c1Cl)O AQKWOXKUZVAZIH-UHFFFAOYSA-N 0.000 description 1
- XYLLXPOURSGUQQ-UHFFFAOYSA-N CN1CCC(CC(C2(CCCCC2)O)c2cccc(OC(F)(F)F)c2)CC1 Chemical compound CN1CCC(CC(C2(CCCCC2)O)c2cccc(OC(F)(F)F)c2)CC1 XYLLXPOURSGUQQ-UHFFFAOYSA-N 0.000 description 1
- QTHIUNHDCUHODQ-UHFFFAOYSA-N CN1CCN(CC(C2(CCC2)O)c(cc2)ccc2-c2cccc(Cl)c2)CC1 Chemical compound CN1CCN(CC(C2(CCC2)O)c(cc2)ccc2-c2cccc(Cl)c2)CC1 QTHIUNHDCUHODQ-UHFFFAOYSA-N 0.000 description 1
- DVJHRHZVKDADIW-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCC2)O)c(cc2)cc(-c3ccc(C(F)(F)F)cc3)c2OC)CC1 Chemical compound CN1CCN(CC(C2(CCCCC2)O)c(cc2)cc(-c3ccc(C(F)(F)F)cc3)c2OC)CC1 DVJHRHZVKDADIW-UHFFFAOYSA-N 0.000 description 1
- FWQHJBAJMBRTFN-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2ccccc2)CC1 Chemical compound CN1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2ccccc2)CC1 FWQHJBAJMBRTFN-UHFFFAOYSA-N 0.000 description 1
- ARTWLJZNTGQVDX-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2-c2ccccc2)CC1 Chemical compound CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2-c2ccccc2)CC1 ARTWLJZNTGQVDX-UHFFFAOYSA-N 0.000 description 1
- FRKAKPDTDXVBCL-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2OCC2CCCCC2)CC1 Chemical compound CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2OCC2CCCCC2)CC1 FRKAKPDTDXVBCL-UHFFFAOYSA-N 0.000 description 1
- UZQKTBGZTJNWLO-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2OCc(ccc(Br)c2)c2F)CC1 Chemical compound CN1CCN(CC(C2(CCCCC2)O)c(cc2)ccc2OCc(ccc(Br)c2)c2F)CC1 UZQKTBGZTJNWLO-UHFFFAOYSA-N 0.000 description 1
- TXPSUDIPBNUSFB-UHFFFAOYSA-N CN1CCN(CC(C2(CCCCCCC2)O)c2cccc3ccccc23)CC1 Chemical compound CN1CCN(CC(C2(CCCCCCC2)O)c2cccc3ccccc23)CC1 TXPSUDIPBNUSFB-UHFFFAOYSA-N 0.000 description 1
- JFXBSBXULPFEEL-UHFFFAOYSA-N CN1CCN(CC(C2(CCOCC2)O)c2cc(Cl)ccc2)CC1 Chemical compound CN1CCN(CC(C2(CCOCC2)O)c2cc(Cl)ccc2)CC1 JFXBSBXULPFEEL-UHFFFAOYSA-N 0.000 description 1
- DLDRVDRDOQTYDC-LFQPHHBNSA-N CN[C@@H]1CN(CC(C2(CCCCC2)O)c(cc2)ccc2OCc2ccccc2)CC1 Chemical compound CN[C@@H]1CN(CC(C2(CCCCC2)O)c(cc2)ccc2OCc2ccccc2)CC1 DLDRVDRDOQTYDC-LFQPHHBNSA-N 0.000 description 1
- FSKRAXWGFULMLI-UHFFFAOYSA-N COC1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2ccccc2)CC1 Chemical compound COC1CCN(CC(C2(CCCCC2)O)c(cc2)cc(Cl)c2OCc2ccccc2)CC1 FSKRAXWGFULMLI-UHFFFAOYSA-N 0.000 description 1
- DNBPJNAVOUURTN-UHFFFAOYSA-N COc(cc(C(CN(CC1)CCC1N)C1(CCCCC1)O)cc1)c1OCc1ccccc1 Chemical compound COc(cc(C(CN(CC1)CCC1N)C1(CCCCC1)O)cc1)c1OCc1ccccc1 DNBPJNAVOUURTN-UHFFFAOYSA-N 0.000 description 1
- TVSYBCAJYFUDQY-UHFFFAOYSA-N COc(cc(C(CN1CCNCC1)C1(CCCCC1)O)cc1)c1OCc1ccc(C(F)(F)F)cc1 Chemical compound COc(cc(C(CN1CCNCC1)C1(CCCCC1)O)cc1)c1OCc1ccc(C(F)(F)F)cc1 TVSYBCAJYFUDQY-UHFFFAOYSA-N 0.000 description 1
- QTCJBSVMNVQVCG-UHFFFAOYSA-N COc(ccc(C(CN(CC1)CCC1N)C1(CCCCC1)O)c1)c1Br Chemical compound COc(ccc(C(CN(CC1)CCC1N)C1(CCCCC1)O)c1)c1Br QTCJBSVMNVQVCG-UHFFFAOYSA-N 0.000 description 1
- XDKDKPVYMZPDQK-UHFFFAOYSA-N COc1cc(C(CN2CCNCC2)C2(CCCCC2)O)ccc1OCc1ccccc1 Chemical compound COc1cc(C(CN2CCNCC2)C2(CCCCC2)O)ccc1OCc1ccccc1 XDKDKPVYMZPDQK-UHFFFAOYSA-N 0.000 description 1
- MMDUWVWJBALJKF-UHFFFAOYSA-N COc1cccc(-c2cccc(C(CN3CCNCC3)C3(CCCCC3)O)c2)c1 Chemical compound COc1cccc(-c2cccc(C(CN3CCNCC3)C3(CCCCC3)O)c2)c1 MMDUWVWJBALJKF-UHFFFAOYSA-N 0.000 description 1
- SYDHDMZQQDHESM-HJPAWNECSA-N C[C@@H](COC([C@H](C)C[C@@H](C1)C(CNCCNC)C2(CCCCC2)O)C1Cl)C(F)(F)F Chemical compound C[C@@H](COC([C@H](C)C[C@@H](C1)C(CNCCNC)C2(CCCCC2)O)C1Cl)C(F)(F)F SYDHDMZQQDHESM-HJPAWNECSA-N 0.000 description 1
- IZKKWMODPZOVDT-QFBILLFUSA-N C[C@@H]1N(C)CCN(C[C@@H](C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)C1 Chemical compound C[C@@H]1N(C)CCN(C[C@@H](C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)C1 IZKKWMODPZOVDT-QFBILLFUSA-N 0.000 description 1
- JDHYMMXARQOHBD-HDWPHTRQSA-N C[C@H](C/C=C\[C@H](C)C#N)/C(/C)=C/CC[C@@](C)(CN1CCNCC1)C1(CCCCC1)O Chemical compound C[C@H](C/C=C\[C@H](C)C#N)/C(/C)=C/CC[C@@](C)(CN1CCNCC1)C1(CCCCC1)O JDHYMMXARQOHBD-HDWPHTRQSA-N 0.000 description 1
- TTYCOWSNRXQRHZ-NXJLTJBGSA-N C[C@H](CC1)CC1([C@H](CN(CC1)CCC1N1CCCCC1)c1cc(OC(F)(F)F)ccc1)O Chemical compound C[C@H](CC1)CC1([C@H](CN(CC1)CCC1N1CCCCC1)c1cc(OC(F)(F)F)ccc1)O TTYCOWSNRXQRHZ-NXJLTJBGSA-N 0.000 description 1
- ZNDZJNVJUAKEQC-JTDSTZFVSA-N C[C@H]1N[C@@H](C)CN(C[C@@H](C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)C1 Chemical compound C[C@H]1N[C@@H](C)CN(C[C@@H](C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)C1 ZNDZJNVJUAKEQC-JTDSTZFVSA-N 0.000 description 1
- IKRRMRWHRBSRTL-LDCVWXEPSA-N N[C@H]1CN(CC(C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)CC1 Chemical compound N[C@H]1CN(CC(C2(CCCCC2)O)c2cc(OC(F)(F)F)ccc2)CC1 IKRRMRWHRBSRTL-LDCVWXEPSA-N 0.000 description 1
- OHMTWGZXZSRAPD-UHFFFAOYSA-N OC1(CCC1)C(CN1CCNCC1)c(cc1)ccc1OC(F)(F)F Chemical compound OC1(CCC1)C(CN1CCNCC1)c(cc1)ccc1OC(F)(F)F OHMTWGZXZSRAPD-UHFFFAOYSA-N 0.000 description 1
- NEHUOIKTKJKISZ-UHFFFAOYSA-N OC1(CCC1)C(CN1CCNCC1)c1cc(OC(F)(F)F)ccc1 Chemical compound OC1(CCC1)C(CN1CCNCC1)c1cc(OC(F)(F)F)ccc1 NEHUOIKTKJKISZ-UHFFFAOYSA-N 0.000 description 1
- VFQONXBNIYKOHH-UHFFFAOYSA-N OC1(CCC1)C(CN1CCOCC1)c1cc(Br)ccc1 Chemical compound OC1(CCC1)C(CN1CCOCC1)c1cc(Br)ccc1 VFQONXBNIYKOHH-UHFFFAOYSA-N 0.000 description 1
- POZPNSNUOULCSM-UHFFFAOYSA-N OC1(CCC1)C(CN1CCOCC1)c1cc2ccccc2cc1 Chemical compound OC1(CCC1)C(CN1CCOCC1)c1cc2ccccc2cc1 POZPNSNUOULCSM-UHFFFAOYSA-N 0.000 description 1
- SFWRFMDEESRSPD-UHFFFAOYSA-N OC1(CCC1)C(CNCc1ccccc1)c(cc1)cc(Cl)c1Cl Chemical compound OC1(CCC1)C(CNCc1ccccc1)c(cc1)cc(Cl)c1Cl SFWRFMDEESRSPD-UHFFFAOYSA-N 0.000 description 1
- DCOXRBWGYKLYDY-UHFFFAOYSA-N OC1(CCCCC1)C(CN(CC1)CCC1N1CCCC1)c1cc(OC(F)(F)F)ccc1 Chemical compound OC1(CCCCC1)C(CN(CC1)CCC1N1CCCC1)c1cc(OC(F)(F)F)ccc1 DCOXRBWGYKLYDY-UHFFFAOYSA-N 0.000 description 1
- NAKNQHNRCTUEDV-UHFFFAOYSA-N OC1(CCCCC1)C(CN(CC1)CCC1N1CCCCC1)c1cc(C(F)(F)F)ccc1 Chemical compound OC1(CCCCC1)C(CN(CC1)CCC1N1CCCCC1)c1cc(C(F)(F)F)ccc1 NAKNQHNRCTUEDV-UHFFFAOYSA-N 0.000 description 1
- OLFNVMSZWXRUHS-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCN(CC2CCCCC2)CC1)c1cc(Oc2ccccc2)ccc1 Chemical compound OC1(CCCCC1)C(CN1CCN(CC2CCCCC2)CC1)c1cc(Oc2ccccc2)ccc1 OLFNVMSZWXRUHS-UHFFFAOYSA-N 0.000 description 1
- NYTNRNAENATURO-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCN(Cc2cc3ccccc3[o]2)CC1)c1cc(Cl)ccc1 Chemical compound OC1(CCCCC1)C(CN1CCN(Cc2cc3ccccc3[o]2)CC1)c1cc(Cl)ccc1 NYTNRNAENATURO-UHFFFAOYSA-N 0.000 description 1
- NMKFVSKZZUWFCB-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCN(Cc2ccccc2)CCC1)c(cc1)ccc1OC(F)(F)F Chemical compound OC1(CCCCC1)C(CN1CCN(Cc2ccccc2)CCC1)c(cc1)ccc1OC(F)(F)F NMKFVSKZZUWFCB-UHFFFAOYSA-N 0.000 description 1
- QVVYUPDVPHVIPQ-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCNCC1)c([s]1)ccc1Cl Chemical compound OC1(CCCCC1)C(CN1CCNCC1)c([s]1)ccc1Cl QVVYUPDVPHVIPQ-UHFFFAOYSA-N 0.000 description 1
- WQHZXZZOAWQOPK-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCNCC1)c(cc1)ccc1OCCc1ccccc1 Chemical compound OC1(CCCCC1)C(CN1CCNCC1)c(cc1)ccc1OCCc1ccccc1 WQHZXZZOAWQOPK-UHFFFAOYSA-N 0.000 description 1
- SFRUDVVIRONFKI-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCNCC1)c1cc(-c(cc2)ccc2Cl)ccc1 Chemical compound OC1(CCCCC1)C(CN1CCNCC1)c1cc(-c(cc2)ccc2Cl)ccc1 SFRUDVVIRONFKI-UHFFFAOYSA-N 0.000 description 1
- OVOXVCGLRYMTSR-UHFFFAOYSA-N OC1(CCCCC1)C(CN1CCNCC1)c1ccccc1-c(cc1Cl)ccc1Cl Chemical compound OC1(CCCCC1)C(CN1CCNCC1)c1ccccc1-c(cc1Cl)ccc1Cl OVOXVCGLRYMTSR-UHFFFAOYSA-N 0.000 description 1
- VVXCBCQJMPIPOX-UHFFFAOYSA-N OC1(CCCCC1)C(CNCc1ccc(C(F)(F)F)cc1)c(cc1)cc(Cl)c1Cl Chemical compound OC1(CCCCC1)C(CNCc1ccc(C(F)(F)F)cc1)c(cc1)cc(Cl)c1Cl VVXCBCQJMPIPOX-UHFFFAOYSA-N 0.000 description 1
- UDBKTSSKQXOPDG-UHFFFAOYSA-N OC1(CCCCC1)C(CNCc1ccccc1)c1cc(Br)ccc1 Chemical compound OC1(CCCCC1)C(CNCc1ccccc1)c1cc(Br)ccc1 UDBKTSSKQXOPDG-UHFFFAOYSA-N 0.000 description 1
- BQEZGUPVHCLNQB-XMMPIXPASA-N OC1(CCCCC1)[C@H](CN1CCN(Cc2ccccc2)CC1)c1cc(OC(F)(F)F)ccc1 Chemical compound OC1(CCCCC1)[C@H](CN1CCN(Cc2ccccc2)CC1)c1cc(OC(F)(F)F)ccc1 BQEZGUPVHCLNQB-XMMPIXPASA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51100203P | 2003-10-14 | 2003-10-14 | |
| US56145304P | 2004-04-12 | 2004-04-12 | |
| US57004304P | 2004-05-11 | 2004-05-11 | |
| US10/962,881 US7524846B2 (en) | 2003-10-14 | 2004-10-12 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| PCT/US2004/033670 WO2005037807A1 (en) | 2003-10-14 | 2004-10-13 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508392A true JP2007508392A (ja) | 2007-04-05 |
| JP2007508392A5 JP2007508392A5 (enExample) | 2007-11-29 |
Family
ID=34468488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535598A Pending JP2007508392A (ja) | 2003-10-14 | 2004-10-13 | アリールアルキルおよびシクロアルキルアルキル−ピペラジン誘導体およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7524846B2 (enExample) |
| EP (1) | EP1678154A1 (enExample) |
| JP (1) | JP2007508392A (enExample) |
| AU (1) | AU2004282164A1 (enExample) |
| BR (1) | BRPI0415410A (enExample) |
| CA (1) | CA2539761A1 (enExample) |
| MX (1) | MXPA06003881A (enExample) |
| WO (1) | WO2005037807A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491723B2 (en) * | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| US7531543B2 (en) * | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US7414052B2 (en) * | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| JP2008512417A (ja) * | 2004-09-10 | 2008-04-24 | ユセベ ファルマ ソシエテ アノニム | シグマ受容体リガンド |
| US20070021488A1 (en) * | 2005-07-21 | 2007-01-25 | Wyeth | Method for treating nervous system disorders and conditions |
| WO2007067575A2 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for preparing substituted aryl cycloalkanol derivatives |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2636032A (en) * | 1949-04-12 | 1953-04-21 | Abbott Lab | N, n'-disubstituted piperazines and process of preparing same |
| US2971955A (en) * | 1958-12-29 | 1961-02-14 | Abbott Lab | Cyclohexylcarbinol derivatives of piperazine |
| GB1243955A (en) * | 1969-03-28 | 1971-08-25 | Delalande Sa | Novel n-substituted amines and their process of preparation |
| JPH01121281A (ja) * | 1987-09-30 | 1989-05-12 | American Home Prod Corp | 置換1−[アラルキル−ピペラジノアルキル]シクロアルカノール |
| JP2003518064A (ja) * | 1999-12-20 | 2003-06-03 | ニューロメド テクノロジーズ, インコーポレイテッド | 置換ピペラジンおよびピペリジンカルシウムチャネルブロッカー |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454554A (en) * | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
| CS175831B1 (enExample) | 1974-12-17 | 1977-05-31 | ||
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
| PH18686A (en) | 1981-05-26 | 1985-08-29 | Merck & Co Inc | 1-(3 halo-2-pyridinyl) piperazine |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| ZA864772B (en) | 1985-07-02 | 1987-02-25 | Merrell Dow Pharma | Novel chemical compounds |
| CA1327795C (en) | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| ATE114467T1 (de) | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol. |
| US5502047A (en) * | 1993-03-22 | 1996-03-26 | Kavey; Neil B. | Treatment for insomnia |
| CZ296263B6 (cs) | 1996-03-25 | 2006-02-15 | Eli Lilly And Company | Farmaceutická kompozice pro lécení bolesti a jejípouzití |
| KR20010015918A (ko) | 1998-03-02 | 2001-02-26 | 피터 지. 스트링거 | 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드 |
| ES2305606T3 (es) | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
| JP2003503450A (ja) * | 1999-07-01 | 2003-01-28 | ファルマシア・アンド・アップジョン・カンパニー | 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法 |
| ATE369330T1 (de) | 2001-02-12 | 2007-08-15 | Wyeth Corp | O-desmethyl-venlafaxine succinat salz |
| EP1383495A1 (en) | 2001-03-29 | 2004-01-28 | Eli Lilly And Company | Duloxetine for treatment of hot flashes |
| EP1266659A1 (en) | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US20040259850A1 (en) | 2001-10-31 | 2004-12-23 | Alves Stephen E. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| EP1468990A4 (en) | 2001-12-21 | 2006-01-04 | Taisho Pharmaceutical Co Ltd | PIPERAZINE DERIVATIVE |
| PL223471B1 (pl) | 2002-03-15 | 2016-10-31 | Cypress Bioscience Inc | Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| CA2495452A1 (en) | 2002-08-14 | 2004-02-26 | Pharmacia & Upjohn Company Llc | Use of reboxetine for the treatment of hot flashes |
| US20040152710A1 (en) | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
| US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US7491723B2 (en) * | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| US7531543B2 (en) * | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
-
2004
- 2004-10-12 US US10/962,881 patent/US7524846B2/en not_active Expired - Fee Related
- 2004-10-13 AU AU2004282164A patent/AU2004282164A1/en not_active Abandoned
- 2004-10-13 EP EP04794904A patent/EP1678154A1/en not_active Withdrawn
- 2004-10-13 WO PCT/US2004/033670 patent/WO2005037807A1/en not_active Ceased
- 2004-10-13 JP JP2006535598A patent/JP2007508392A/ja active Pending
- 2004-10-13 BR BRPI0415410-0A patent/BRPI0415410A/pt not_active IP Right Cessation
- 2004-10-13 MX MXPA06003881A patent/MXPA06003881A/es unknown
- 2004-10-13 CA CA002539761A patent/CA2539761A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2636032A (en) * | 1949-04-12 | 1953-04-21 | Abbott Lab | N, n'-disubstituted piperazines and process of preparing same |
| US2971955A (en) * | 1958-12-29 | 1961-02-14 | Abbott Lab | Cyclohexylcarbinol derivatives of piperazine |
| GB1243955A (en) * | 1969-03-28 | 1971-08-25 | Delalande Sa | Novel n-substituted amines and their process of preparation |
| JPH01121281A (ja) * | 1987-09-30 | 1989-05-12 | American Home Prod Corp | 置換1−[アラルキル−ピペラジノアルキル]シクロアルカノール |
| JP2003518064A (ja) * | 1999-12-20 | 2003-06-03 | ニューロメド テクノロジーズ, インコーポレイテッド | 置換ピペラジンおよびピペリジンカルシウムチャネルブロッカー |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2539761A1 (en) | 2005-04-28 |
| MXPA06003881A (es) | 2006-07-03 |
| EP1678154A1 (en) | 2006-07-12 |
| BRPI0415410A (pt) | 2006-12-05 |
| US20050148595A1 (en) | 2005-07-07 |
| US7524846B2 (en) | 2009-04-28 |
| AU2004282164A1 (en) | 2005-04-28 |
| WO2005037807A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090227585A1 (en) | Substituted n-heterocycle derivatives and methods of their use | |
| US7550456B2 (en) | Substituted aryl cycloalkanoyl derivatives and methods of their use | |
| JP2007509073A (ja) | アルカノールおよびシクロアルカノール−アミン誘導体およびその使用方法 | |
| JP2007508393A (ja) | 縮合アリールおよびヘテロアリール誘導体およびその使用方法 | |
| JP2007508392A (ja) | アリールアルキルおよびシクロアルキルアルキル−ピペラジン誘導体およびその使用方法 | |
| US7402698B2 (en) | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | |
| CN1972920A (zh) | 用于治疗因单胺的再吸收而得以改善的包括血管舒缩症的病症的芳烷基哌嗪衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071012 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |